These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17890828)

  • 1. Pharmacovigilance in kala-azar patients with severe thrombocytopenia caused by sodium antimony gluconate & miltefosine.
    Thakur CP; Kumar A; Mitra G; Thakur S; Thakur M
    Indian J Med Res; 2007 Jul; 126(1):73-5. PubMed ID: 17890828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
    Thakur CP; Thakur S; Narayan S; Sinha A
    Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar.
    Maheshwari A; Seth A; Kaur S; Aneja S; Rath B; Basu S; Patel R; Dutta AK
    Pediatr Infect Dis J; 2011 Feb; 30(2):180-1. PubMed ID: 20823781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
    Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
    Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial of oral miltefosine for visceral leishmaniasis.
    Sundar S; Rosenkaimer F; Makharia MK; Goyal AK; Mandal AK; Voss A; Hilgard P; Murray HW
    Lancet; 1998 Dec; 352(9143):1821-3. PubMed ID: 9851383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral miltefosine for Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
    N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does antimony therapy cause bleeding in kala-azar patients and why?
    Chowdhury MA; Ahasan HA; Azhar MA; Rafiqueuddin AK; Islam MR; Misbahuddin M; Rashid MU
    Trop Doct; 1995 Oct; 25(4):188-9. PubMed ID: 7502336
    [No Abstract]   [Full Text] [Related]  

  • 9. Ambisome plus miltefosine for Indian patients with kala-azar.
    Sundar S; Sinha PK; Verma DK; Kumar N; Alam S; Pandey K; Kumari P; Ravidas V; Chakravarty J; Verma N; Berman J; Ghalib H; Arana B
    Trans R Soc Trop Med Hyg; 2011 Feb; 105(2):115-7. PubMed ID: 21129762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
    Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN
    Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.
    Singh UK; Prasad R; Mishra OP; Jayswal BP
    Indian J Pediatr; 2006 Dec; 73(12):1077-80. PubMed ID: 17202633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
    Thakur CP; Narayan S; Ranjan A
    Indian J Med Res; 2004 Sep; 120(3):166-72. PubMed ID: 15489554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new strategy for elimination of kala-azar from rural Bihar.
    Thakur CP
    Indian J Med Res; 2007 Nov; 126(5):447-51. PubMed ID: 18160749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of serum copper in Kala-azar patients during SAG therapy.
    Banerjee M; Rahman M; Shamuzzaman AK; Akhter S; Deb K
    Mymensingh Med J; 2007 Jan; 16(1):89-93. PubMed ID: 17344788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
    Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy in Kala-azar.
    Singh NK; Jha TK; Singh IJ; Jha S
    J Assoc Physicians India; 1995 May; 43(5):319-20. PubMed ID: 9081958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A thirty day course of sodium stibogluconate for treatment of Kala-azar in Nepal.
    Karki P; Koirala S; Parija SC; Hansdak SG; Das ML
    Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):154-8. PubMed ID: 9740292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.